Literature DB >> 2702997

Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell line.

S Sekiya1, T Oosaki, S Andoh, N Suzuki, M Akaboshi, H Takamizawa.   

Abstract

A cis-diamminedichloroplatinum (II) (cisplatin)-resistant subline (Cis-Ptr) demonstrated 20-fold greater resistance to the cytotoxic effects of cisplatin, compared with the parental cloned rat ovarian carcinoma cell line (ROT 68/C1). The uptake of cisplatin into the Cis-Ptr cells was identical to that into the ROT68/C1 cells in vitro and in vivo. Glutathione activity in a cytoplasmic extract was 1.4-fold and 1.8-fold greater in the Cis-Ptr cells than in the ROT68/C1 cells in vitro and in vivo, respectively. There was no difference between the ROT68/C1 and Cis-PTr cells in 195m cisplatin binding per micrograms DNA. DNA repair of cisplatin DNA damage was increased in the Cis-PTr cells but not in the ROT68/C1 cells. These results suggest that the mechanisms of resistance to cisplatin in rat ovarian carcinoma cells involve increased activity of the DNA repair system and increased cytosolic binding to thiols may also be involved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702997     DOI: 10.1016/0277-5379(89)90255-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

1.  N-myc amplification and its relationship to experimental therapy.

Authors:  A Livingstone; R J Mairs
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: dependence on the tumor sensitivity to cisplatin.

Authors:  M C Jäckel; R Tausch-Treml; P Köpf-Maier
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II).

Authors:  J Hansson; R D Wood
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

Review 4.  Chemotherapeutic drug resistance in the management of head and neck cancer.

Authors:  H Bier
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

5.  Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo.

Authors:  G Chen; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.

Authors:  H P Hofs; D J Wagener; V de Valk-Bakker; H van Rennes; A J van Zeist; L A van den Broek; H C Ottenheijm
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.

Authors:  J E Melvik; J M Dornish; E O Pettersen
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

8.  31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance.

Authors:  R Tausch-Treml; P Köpf-Maier; F Baumgart; B Gewiese; D Ziessow; H Scherer; K J Wolf
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.